VALIANTLAB
Valiant Laboratories financials
- Market cap
- ₹695 Cr
- Sector
- Healthcare
What Valiant Laboratories Limited does
Valiant Laboratories Limited manufactures Active Pharmaceutical Ingredients (APIs), with its core business built around Paracetamol API produced in Powder, Fine Powder and Crystals grades meeting IP/BP/USP/EP pharmacopoeia standards. It sells to pharmaceutical companies that use the API to make tablets, capsules and other finished dosage forms, from a single ISO 9001:2015 and GMP-certified manufacturing facility in Tarapur Industrial Estate, Maharashtra, near Mumbai and Nhava Sheva Port. Part of the Aarti Group of Industries, the company is diversifying beyond Paracetamol through its wholly-owned subsidiary Valiant Advanced Sciences Private Limited (VASPL), which is developing ketene and diketene-derivative specialty chemicals at a pilot plant.
Segments
- Paracetamol API
- Specialty Chemicals (VASPL)
- Manufacturing plants
- 1 (single-location facility, Tarapur Industrial Estate, Maharashtra)
- Installed Paracetamol capacity
- 900 MT/month (enhanced from 750 MT/month via equipment modifications, FY25)
- Permanent employees
- 79 (as on 31 March 2025)
- Specialty-chemical products under development (VASPL)
- 12+
- Paracetamol product grades
- 3 (Powder, Fine Powder, Crystals)
- Pharmacopoeia standards met
- 4 (IP, BP, USP, EP)
Quarterly results
Q1 FY27: revenue up 144.7%, net profit up 950.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21 | 35 | 58 | 47 | 46 +119% | 52 +49% | 92 +59% | 115 +145% |
| EBITDA | -7 | 1 | 4 | 2 | 0 +100% | -1 −200% | 5 +25% | 29 +1350% |
| Net profit | -5 | 2 | 1 | 2 | 0 +100% | -7 −450% | 2 +100% | 21 +950% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +52.5% 1Y
1Y: ₹83.87 on 10 Sept 2025 → ₹127.91. High ₹127.91 (11 Sept 2026), low ₹50.93 (18 Mar 2026).
Financials, as filed
Revenue grew 13.8% a year over 2 years, FY24 to FY26. Operating margin widened to 2.5%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹183 Cr | ₹133 Cr | ₹237 Cr |
| Operating profit | ₹-8 Cr | ₹-4 Cr | ₹6 Cr |
| Operating margin | -4.4% | -3.0% | 2.5% |
| Interest | ₹0 Cr | ₹0 Cr | ₹2 Cr |
| Depreciation | ₹1 Cr | ₹4 Cr | ₹7 Cr |
| Net profit | ₹0 Cr | ₹-3 Cr | ₹-3 Cr |
| Net margin | 0.0% | -2.3% | -1.3% |
| Cash from operations | ₹2 Cr | ₹1 Cr | ₹-10 Cr |
| Free cash flow | ₹-44 Cr | ₹-112 Cr | ₹-45 Cr |
| ROCE | -2.0% | -1.0% | 1.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Equity capital | ₹33 Cr | ₹43 Cr | ₹54 Cr | ₹54 Cr |
| Reserves | ₹68 Cr | ₹193 Cr | ₹263 Cr | ₹257 Cr |
| Borrowings | ₹60 Cr | ₹77 Cr | ₹54 Cr | ₹46 Cr |
| Other liabilities | ₹52 Cr | ₹29 Cr | ₹54 Cr | ₹107 Cr |
| Total liabilities | ₹213 Cr | ₹343 Cr | ₹425 Cr | ₹464 Cr |
| Fixed assets | ₹48 Cr | ₹50 Cr | ₹48 Cr | ₹227 Cr |
| Capital work in progress | ₹1 Cr | ₹43 Cr | ₹174 Cr | ₹6 Cr |
| Investments | ₹34 Cr | ₹38 Cr | ₹48 Cr | ₹28 Cr |
| Other assets | ₹130 Cr | ₹212 Cr | ₹155 Cr | ₹202 Cr |
| Total assets | ₹213 Cr | ₹343 Cr | ₹425 Cr | ₹464 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, the public added +1.09 pp while FIIs trimmed −0.63 pp.
- Promoters
- 74.9%
- Public
- 25.1%
Since Jun 2025
- Public +1.09 pp
- FIIs −0.63 pp
- DIIs −0.46 pp
How it drifted, 12 quarters
Over this window the public went from 14.7% to 25.1% — +10.4 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 74.9%, FIIs 8.6%, DIIs 1.8%, Public 14.7%.Dec '23: Promoters 74.9%, FIIs 7.1%, DIIs 0.4%, Public 17.5%.Mar '24: Promoters 74.9%, FIIs 3.5%, Public 21.6%.Jun '24: Promoters 74.9%, FIIs 1.9%, Public 23.2%.Sep '24: Promoters 74.9%, Public 25.1%.Dec '24: Promoters 74.9%, Public 25.1%.Mar '25: Promoters 74.9%, FIIs 0.6%, Public 24.4%.Jun '25: Promoters 74.9%, FIIs 0.6%, DIIs 0.5%, Public 24.0%.Sep '25: Promoters 74.9%, FIIs 0.0%, Public 25.1%.Dec '25: Promoters 74.9%, FIIs 0.0%, Public 25.1%.Mar '26: Promoters 74.9%, FIIs 0.2%, Public 24.9%.Jun '26: Promoters 74.9%, Public 25.1%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Anil Vishanji Dedhia +0.55 pp 1.84% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Valiant Laboratories Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Dhanvallabh Ventures LLP | 46.84% | unchanged |
| Paresh Shashikant Shah | 9.36% | unchanged |
| Santosh Shantilal Vora | 7.50% | unchanged |
| Shanilal Shivji Vora | 7.50% | unchanged |
| Kanchan Shantilal Vora | 3.72% | unchanged |
| Anil Vishanji Dedhia | 1.84% | +0.55 pp |
| Rachi Santosh Vora | 0.02% | unchanged |
| Varsha Paresh Shah | 0.01% | unchanged |
| Sangita Manoj Jain | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Valiant Laboratories Limited
Guides on how to read this kind of business and the numbers that matter.